Inmunoterapia en el mieloma múltiple
Medicina Clínica · 2024
DOI: 10.1016/j.medcli.2023.11.019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicina Clínica, 2024. Verfasst von Pedro Asensi Cantó und 2 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Hematología y Hemoterapia, Hospital Universitario y Politécnico La Fe, Valencia, España. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Immunotherapy. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
Patients with multiple myeloma who present with refractory disease or relapse after receiving the main classes of available drugs -immunomodulators, proteasome inhibitors and antibodies against CD38- do not have satisfactory therapeutic alternatives. New treatments based on the redirection of T lymphocytes to act directly against tumor cells, such as bispecific antibodies and T cells with chimeric antigen receptors, are changing this scenario. The published information confirms unprecedented antitumor activity of these agents in patients with refractory myeloma and they will certainly represent the backbone of the treatment of these patients in the immediate future. However, these therapies also present specific characteristics and medium or long-term toxicities that pose new healthcare challenges. In this review, we address the current results and future challenges of the administration of these treatments in patients with relapsed or refractory multiple myeloma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Hematología y Hemoterapia, Hospital Universitario y Politécnico La Fe, Valencia, España.
- Servicio de Hematología y Hemoterapia, Hospital Universitario y Politécnico La Fe, Valencia, España; Facultad de Medicina y Odontología, Universidad Católica de Valencia, Valencia, España; Instituto de Investigación San…
Zitieren
APA
Asensi Cantó, P., Arnao Herraiz, M., & de la Rubia Comos, J. (2024). Inmunoterapia en el mieloma múltiple. Medicina Clínica. https://doi.org/10.1016/j.medcli.2023.11.019
Vancouver
Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J. Inmunoterapia en el mieloma múltiple. Medicina Clínica. 2024. doi:10.1016/j.medcli.2023.11.019
BibTeX
@article{AsensiCant2024,
author = {Asensi Cantó, Pedro and Arnao Herraiz, Mario and de la Rubia Comos, Javier},
title = {Inmunoterapia en el mieloma múltiple},
journal = {Medicina Clínica},
year = {2024},
doi = {10.1016/j.medcli.2023.11.019}
}
EUVIMED